Zealand Pharma Management

Management criteria checks 3/4

Zealand Pharma's CEO is Adam Steensberg, appointed in Mar 2022, has a tenure of 2.08 years. total yearly compensation is DKK24.84M, comprised of 23.2% salary and 76.8% bonuses, including company stock and options. directly owns 0.069% of the company’s shares, worth €3.58M. The average tenure of the management team and the board of directors is 3 years and 9 years respectively.

Key information

Adam Steensberg

Chief executive officer

kr.24.8m

Total compensation

CEO salary percentage	23.2%
CEO tenure	2.1yrs
CEO ownership	0.07%
Management average tenure	3yrs
Board average tenure	9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Adam Steensberg's remuneration changed compared to Zealand Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr.25m	kr.6m	-kr.704m
Sep 30 2023	n/a	n/a	-kr.760m
Jun 30 2023	n/a	n/a	-kr.986m
Mar 31 2023	n/a	n/a	-kr.1b
Dec 31 2022	kr.19m	kr.4m	-kr.966m
Sep 30 2022	n/a	n/a	-kr.855m
Jun 30 2022	n/a	n/a	-kr.845m
Mar 31 2022	n/a	n/a	-kr.608m
Dec 31 2021	kr.10m	kr.3m	-kr.755m
Sep 30 2021	n/a	n/a	-kr.925m
Jun 30 2021	n/a	n/a	-kr.1b
Mar 31 2021	n/a	n/a	-kr.909m
Dec 31 2020	kr.7m	kr.3m	-kr.669m
Sep 30 2020	n/a	n/a	-kr.660m
Jun 30 2020	n/a	n/a	-kr.545m
Mar 31 2020	n/a	n/a	-kr.624m
Dec 31 2019	kr.7m	kr.3m	-kr.572m

Compensation vs Market: Adam's total compensation ($USD3.56M) is about average for companies of similar size in the German market ($USD3.56M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.

CEO

Adam Steensberg (49 yo)

2.1yrs

Tenure

kr.24,837,000

Compensation

Mr. Adam Sinding Steensberg, M.D., serves as President and Chief Executive Officer at Zealand Pharma A/S since March 30, 2022. He had been an Executive Vice President of Research & Development and Chief Me...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Adam Steensberg	President & CEO	2.1yrs	kr.24.84m	0.069% DKK 3.6m
Henriette Wennicke	EVP & CFO	1.4yrs	kr.9.24m	0.0055% DKK 286.3k
Ivan Moller	Executive VP & COO	6.1yrs	no data	0.073% DKK 3.8m
David Kendall	Chief Medical Officer and Head of R&D	no data	no data	0.015% DKK 775.7k
Mads Kronborg	Head of Investor Relations & Communication	3.7yrs	no data	no data
Ravinder Chahil	EVP & General Counsel	2.3yrs	no data	0.012% DKK 611.5k
Christina Bredal	Executive VP & Chief People Officer	3yrs	no data	0.011% DKK 561.6k
Jens Mikkelsen	Head of Molecular Pharmacology	no data	no data	no data
Danilo Verge	Head of Global Medical Affairs	3.6yrs	no data	no data
Lykke Romer	VP & Head of Finance and Accounting	no data	no data	no data
Miriam Katz	Assistant Secretary	no data	no data	no data
Anna Krassowska	Vice President of Investor Relations & Corporate Communications	no data	no data	no data

3.0yrs

Average Tenure

50yo

Average Age

Experienced Management: 22Z's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Leonard Kruimer	Independent Director	5yrs	kr.764.00k	0.025% DKK 1.3m
Alf Gunnar Nicklasson	Independent Chairman of the Board	9yrs	kr.1.07m	0.030% DKK 1.5m
Kirsten Drejer	Independent Vice Chairman	6yrs	kr.583.00k	0.014% DKK 734.1k
Ake Lernmark	Member of Advisory Board	12.4yrs	no data	no data
Gudmund Korsgard	Board Observer	no data	no data	no data
Jeffrey Berkowitz	Independent Director	5yrs	kr.583.00k	0.013% DKK 684.2k
Bernard Charbonnel	Member of Advisory Board	12.4yrs	no data	no data
Richard Pratley	Member of Advisory Board	12.4yrs	no data	no data
Paul Dorian	Member of Advisory Board	12.4yrs	no data	no data
Gert Van Assche	Member of Advisory Board	12.4yrs	no data	no data
Bernadette Connaughton	Independent Director	5yrs	kr.583.00k	0.014% DKK 709.2k
Nikolaj Barfoed Beck	Employee Representative Director	4yrs	kr.281.00k	0.0058% DKK 302.4k

9.0yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 22Z's board of directors are considered experienced (9 years average tenure).

Zealand Pharma Management

Management criteria checks 3/4

Key information

Recent management updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Recent updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021)

Insufficient new directors

Zealand Pharma Announces CEO Changes

Full year 2021 earnings: Revenues in line with analyst expectations

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020)

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Full year 2020 earnings released: kr.22.07 loss per share (vs kr.16.91 loss in FY 2019)

Revenue misses expectations

New 90-day low: €25.56

New 90-day low: €27.18

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Revenue misses expectations

Third quarter 2020 earnings released: kr.5.76 loss per share

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

New 90-day high: €33.36

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

New 90-day low - €29.52

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age